Combined Digital Colposcopy Analysis to Improve Cervical Precancer and Cancer Detection (MDC_Algo)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2015 by British Columbia Cancer Agency
National Cancer Institute (NCI)
Texas Tech University Health Sciences Center
Brookdale University Hospital Medical Center
William Marsh Rice University
The University of Texas Health Science Center, Houston
M.D. Anderson Cancer Center
Information provided by (Responsible Party):
British Columbia Cancer Agency Identifier:
First received: March 25, 2010
Last updated: September 1, 2015
Last verified: August 2015

Precancerous lesions of the cervix occur frequently and are treatable. This justifies a population-based screening program. Following an abnormal Pap smear, patients are referred for a colposcopic exam to confirm the presence/stage of disease and select appropriate treatments. Unfortunately, these approaches do not detect all lesions or can sometimes give 'false positive' results (resulting in overtreatment). We are testing a device called a 'multispectral digital colposcope' to determine whether it is more effective at detecting precancerous cervical lesions than existing tools. Success in our study will make diagnoses more accurate and reduce the costs associated with unnecessary treatments.

Condition Intervention Phase
Cervical Cancer
Precancerous Condition
Device: Multispectral Digital Colposcope (MDC)
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Development and Application of a Multispectral Digital Colposcopy Algorithm for Detection of Cervical Intraepithelial Neoplasia and Neoplasia.

Resource links provided by NLM:

Further study details as provided by British Columbia Cancer Agency:

Primary Outcome Measures:
  • Detection of cancer or pre-cancerous abnormalities of the cervix by multispectral digital colposcope. [ Time Frame: Standard colposcopy and trial device (MDC + wand) results will be obtained during the clinic visit. Histopathological results for comparison will be available within a few days of the clinic visit. ] [ Designated as safety issue: No ]
    All study subjects will be evaluated for cervical abnormalities by 1) standard colposcopy and 2) the trial device (multispectral digital colposcope + wand). Results from each device will be compared, both in terms of the presence/absence of abnormalities and the stage/grade of abnormalities detected by both tools. Histopathological review for cervical abnormalities will be taken as the gold standard against which standard colposcopy and trial device results are measured.

Estimated Enrollment: 618
Study Start Date: December 2012
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Review by colposcopy + multispectral digital colposcopy
All patients belong under this arm, as all will be reviewed by both conventional colposcopy and by Multispectral Digital Colposcopy (MDC). The nature of these techniques are explained below.
Device: Multispectral Digital Colposcope (MDC)

The MDC has 2 components: an optical probe & a multispectral colposcope. The optical wand makes use of fluorescence & reflectance spectroscopy; a light is shone on the cervix and the wand reports what it sees to a computer. Since cancer & healthy cells interact differently with light, a computer can detect abnormalities. The multispectral colposcope is based on a conventional colposcope, which is already widely used. However, it is also able to produce fluorescence & polarized reflectance images of the entire cervix. Computer analysis of these images can detect abnormalities on the cervix, defining their location and shape.

This trial involves combined analysis of MDC data. This may lead to more effective diagnosis of cervical abnormalities. The MDC will be used with standard care for patients presenting with cervical abnormalities (as detected by a Pap test). The MDC will not be used to guide patient management decisions.

All study subjects will receive this same intervention.

Detailed Description:

The multispectral digital colposcope (MDC) is a specialized lightsource and imaging device mounted on a custom-made colposcope that acquires a sequence of fluorescence images. The MDC also consists of a point probe that is used to take detailed light measurements (call spectroscopy) from smaller regions of the cervix. The goal of the study is to see whether the MDC can perform better than standard methods in detecting cancerous or pre-cancerous abnormalities of the cervix.

Study subjects will be HPV swabbed. After vinegar is applied on the cervix as per usual colposcopy practice, the MDC will then be used to take a sequence of images of the cervix. Next 2-4 readings will be taken from the cervix using the point probe.

Study subjects may also be randomly asked to have additional pictures taken with another imaging device. a) The Fast Fluorescence Camera (FFC) is a modified digital camera that will capture images similar to that of the MDC. It will take a pair of images under two different lighting conditions - white light and violet light, both of which are used by the MDC. b) The Confocal Probe (CP) is a hand-held microscope used to collect images from the same location as the point probe. The cervix is topically stained with a fluorescent dye (Acriflavine) which is taken up by cell nuclei. The CP is then able to capture, in real time, images of the cells and their fluorescent nuclei.

This data will be used to train, test and valid an algorithm specific to the MDC. The ability of the algorithm to detect cervical intraepithelial neoplasia will be compared to standard clinical care (colposcopy).

The MDC images and pathology results will be compared to the spectroscopy data from the MDC probe. We will determine if spectroscopy has equal sensitivity to colposcopy for detecting high grade lesions.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Included subjects will be ≥18 years old.
  • Included subjects will not be pregnant or breast feeding.
  • Included subjects will have a negative urine pregnancy test.
  • Included subjects will be scheduled for colposcopy and/or LEEP treatment at the VGH Women's Clinic.
  • Included subjects will indicate understanding of the study.
  • Included subjects will provide informed consent to participate.

Exclusion criteria:

  • Individuals <18 years old will be excluded.
  • Pregnant and breast feeding individuals will be excluded.
  • Individuals that have had an operation to remove their cervix will be excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01094132

Contact: Leonid Fradkin, PhD 718-240-8225

United States, New York
Brookdale Hospital and Medical Center Not yet recruiting
Brooklyn, New York, United States, 11212
Contact: Thelma Carrillo, MPH    718-240-8108   
United States, Texas
Texas Tech Health Sciences Center Completed
El Paso, Texas, United States, 79905
Canada, British Columbia
Vancouver General Hospital - Women's Clinic (G&L Diamond Centre) Recruiting
Vancouver, British Columbia, Canada, V5Z 1M9
Contact: Sylvia Lam    604-675-8093   
Sponsors and Collaborators
British Columbia Cancer Agency
National Cancer Institute (NCI)
Texas Tech University Health Sciences Center
Brookdale University Hospital Medical Center
William Marsh Rice University
The University of Texas Health Science Center, Houston
M.D. Anderson Cancer Center
Principal Investigator: Michele Follen, MD, PhD Brookdale Hospital and Medical Center
  More Information

No publications provided

Responsible Party: British Columbia Cancer Agency Identifier: NCT01094132     History of Changes
Other Study ID Numbers: BCCR-H09-03303, P01CA082710, H09-03303
Study First Received: March 25, 2010
Last Updated: September 1, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by British Columbia Cancer Agency:
cervical cancer
cervical intraepithelial neoplasia grade 1
cervical intraepithelial neoplasia grade 2
cervical intraepithelial neoplasia grade 3
Nonmalignant Condition

Additional relevant MeSH terms:
Cervical Intraepithelial Neoplasia
Precancerous Conditions
Uterine Cervical Neoplasms
Carcinoma in Situ
Genital Diseases, Female
Genital Neoplasms, Female
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urogenital Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Uterine Neoplasms processed this record on October 06, 2015